Literature DB >> 30003403

ECRG4: a new potential target in precision medicine.

Xin Qin1, Ping Zhang2.   

Abstract

Given the rapid development in precision medicine, tremendous efforts have been devoted to discovering new biomarkers for disease diagnosis and treatment. Esophageal cancer-related gene-4 (ECRG4), which is initially known as a new candidate tumor suppressor gene, is emerging as a sentinel molecule for gauging tissue homeostasis. ECRG4 is unique in its cytokine-like functional pattern and epigenetically-regulated gene expression pattern. The gene can be released from the cell membrane upon activation and detected in liquid biopsy, thus offering considerable potential in precision medicine. This review provides an updated summary on the biology of ECRG4, with emphasis on its important roles in cancer diagnosis and therapy. The future perspectives of ECRG4 as a potential molecular marker in precision medicine are also discussed in detail.

Entities:  

Keywords:  ECRG4; cell senescence; epithelium homeostasis; precision medicine; sentinel molecule; tumor suppressor gene

Mesh：

Substances：

Year:  2018        PMID： 30003403     DOI： 10.1007/s11684-018-0637-9

Source DB:  PubMed          Journal:  Front Med        ISSN： 2095-0217            Impact factor:   4.592


  42 in total

1.  Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis.

Authors:  Mojtaba Ghasemi; Iraj Nabipour; Abdolmajid Omrani; Zeinab Alipour; Majid Assadi
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-11-30

2.  Esophageal cancer-related gene 4 is a secreted inducer of cell senescence expressed by aged CNS precursor cells.

Authors:  Yuki Kujuro; Norihiro Suzuki; Toru Kondo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

3.  Identification of novel peptide hormones in the human proteome by hidden Markov model screening.

Authors:  Olivier Mirabeau; Emerald Perlas; Cinzia Severini; Enrica Audero; Olivier Gascuel; Roberta Possenti; Ewan Birney; Nadia Rosenthal; Cornelius Gross
Journal:  Genome Res       Date:  2007-02-06       Impact factor: 9.043

4.  C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes.

Authors:  Jing Lu; Mingxin Wen; Yurong Huang; Xiuquan He; Yunshan Wang; Qi Wu; Zengchun Li; Andres Castellanos-Martin; Mar Abad; Juan J Cruz-Hernandez; Cesar A Rodriguez; Jesús Pérez-Losada; Jian-Hua Mao; Guangwei Wei
Journal:  Epigenetics       Date:  2013-04-26       Impact factor: 4.528

5.  Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis--A short Report.

Authors:  Yanjie You; Haijun Li; Xin Qin; Yonggang Ran; Fei Wang
Journal:  Cell Oncol (Dordr)       Date:  2015-12-02       Impact factor: 6.730

6.  Ecrg4 attenuates the inflammatory proliferative response of mucosal epithelial cells to infection.

Authors:  Arwa Kurabi; Kwang Pak; Xitong Dang; Raul Coimbra; Brian P Eliceiri; Allen F Ryan; Andrew Baird
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

7.  Esophageal cancer related gene-4 is a choroid plexus-derived injury response gene: evidence for a biphasic response in early and late brain injury.

Authors:  Sonia Podvin; Ana-Maria Gonzalez; Miles C Miller; Xitong Dang; Hannah Botfield; John E Donahue; Arwa Kurabi; Matthew Boissaud-Cooke; Ryan Rossi; Wendy E Leadbeater; Conrad E Johanson; Raul Coimbra; Edward G Stopa; Brian P Eliceiri; Andrew Baird
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

8.  Ecrg4 peptide is the ligand of multiple scavenger receptors.

Authors:  Tetsuo Moriguchi; Shuji Takeda; Shinzo Iwashita; Kei Enomoto; Tatsuya Sawamura; Uichi Koshimizu; Toru Kondo
Journal:  Sci Rep       Date:  2018-03-06       Impact factor: 4.379

9.  RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.

Authors:  Lydia Giannopoulou; Issam Chebouti; Kitty Pavlakis; Sabine Kasimir-Bauer; Evi S Lianidou
Journal:  Oncotarget       Date:  2017-03-28

10.  ECRG4 expression in normal rat tissues: expression study and literature review.

Authors:  A Porzionato; M Rucinski; V Macchi; G Sarasin; L K Malendowicz; R De Caro
Journal:  Eur J Histochem       Date:  2015-05-18       Impact factor: 3.188
View more
  4 in total

1.  Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4.

Authors:  Xitong Dang; Raul Coimbra; Liang Mao; Sonia Podvin; Xue Li; Hua Yu; Todd W Costantini; Xiaorong Zeng; Dana Larocca; Brian P Eliceiri; Andrew Baird
Journal:  Cell Mol Life Sci       Date:  2019-06-12       Impact factor: 9.261

2.  ECRG4 acts as a tumor suppressor in nasopharyngeal carcinoma by suppressing the AKT/GSK3β/β-catenin signaling pathway.

Authors:  Zhengyuan Yang; Xiajun Ye; Yujie Zhang; Yiteng Huang; Jian Chen; Yunzhu Zeng; Jiongyu Chen
Journal:  Cytotechnology       Date:  2022-01-27       Impact factor: 2.058

3.  Single-cell multimodal analysis identifies common regulatory programs in synovial fibroblasts of rheumatoid arthritis patients and modeled TNF-driven arthritis.

Authors:  Marietta Armaka; Dimitris Konstantopoulos; Christos Tzaferis; Matthieu D Lavigne; Maria Sakkou; Maria Fousteri; George Kollias; Anastasios Liakos; Petros P Sfikakis; Meletios A Dimopoulos
Journal:  Genome Med       Date:  2022-07-26       Impact factor: 15.266

4.  Loss of Ecrg4 improves calcium oxalate nephropathy.

Authors:  Daniela Cabuzu; Suresh K Ramakrishnan; Matthias B Moor; Dusan Harmacek; Muriel Auberson; Fanny Durussel; Olivier Bonny
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.